| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7888362 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 11 months from now) | |
| USRE48059 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8349840 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 11 months from now) | |
| US9839637 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 11 months from now) | |
| US8618109 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 11 months from now) | |
| US10307419 | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Oct, 2032
(8 years from now) | |
Rexulti is owned by Otsuka.
Rexulti contains Brexpiprazole.
Rexulti has a total of 6 drug patents out of which 0 drug patents have expired.
Rexulti was authorised for market use on 10 July, 2015.
Rexulti is available in tablet;oral dosage forms.
Rexulti can be used as treatment of schizophrenia in adults and pediatric patients ages 13 years and older, adjunctive treatment of major depressive disorder (mdd).
Drug patent challenges can be filed against Rexulti from 11 July, 2019.
The generics of Rexulti are possible to be released after 12 October, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 27, 2024 |
| New Indication(I-913) | May 10, 2026 |
| M(M-186) | Sep 23, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2020 |
Drugs and Companies using BREXPIPRAZOLE ingredient
NCE-1 date: 11 July, 2019
Market Authorisation Date: 10 July, 2015
Treatment: Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
Dosage: TABLET;ORAL
REXULTI family patents
